We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

临床前动物试验中，第三方检测单位的检测结果显示：集团mRNA RSV疫苗特异性IgG抗体滴度、真病毒中和抗体效价、特异性T细胞免疫，均显著高于国际上市的mRNA RSV对照疫苗。

Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

更为重要的是，有了单一的RSV疫苗，每年在呼吸道冬季高发期间，能有效降低感染风险，提升公共卫生水平。对于年轻父母来说，这无疑是一个可喜的消息。保持警惕并主动接种疫苗将成为我们保护婴幼儿健康的首要选择。

艾美疫苗公司正迈出重要步伐，近日宣布其自主研发的mRNA RSV（呼吸道合胞病毒）疫苗向美国食品和药品监督管理局（FDA）提交了临床试验申请。这一里程碑不仅标志着艾美在疫苗研发领域的一次重大进展，也预示着对抗严重影响婴幼儿健康的RSV病毒的希望。 RSV是导致婴幼儿下呼吸道感染的主要病原体，每年在全球范围内造成了大量住院病例。2023年，RSV疫苗的全球销售额已达24.6亿美元，预计到2030年市 ...

The new bill would ban mRNA vaccines for a decade. upi A freshman Idaho lawmaker wants to ban most COVID-19 shots for the ...

InDevR partners with Aldevron to describe how the VaxArray 5′CapQ assay can be used to measure intact mRNA in a single assay to streamline bioprocess development.

目前，全球尚无获批的针对RSV可用于临床的抗病毒特效药，接种疫苗进行主动免疫预防是避免RSV重症感染的有效手段。中国尚无RSV疫苗获批上市，2023年度RSV疫苗的全球销售额为24.6亿美元，根据行业顾问灼识咨询预测，预计到2030年，RSV疫苗在全球的市场规模将达到约167亿美元。该产品如进展顺利，将加快集团的国际化步伐，并给集团带来可观的业绩增长。